Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Yahoo Finance13d
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC). Preliminary data from the SAD portion of the study, which evaluated doses ranging from 15 mg to 450 ...
The American Journal of Managed Care4d
FDA Approves Mirikizumab for Crohn Disease
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Benzinga.com12d
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Over 80% of patients maintained endoscopic response after two years of continuous Omvoh treatment in ongoing studies ...
Palisade's PALI-2108 Shows Tolerability Across 15mg To 450mg Doses In Ulcerative Colitis Study
(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...
health.economictimes.indiatimes11d
Webinar on Living with IBD and choosing the right treatment
Inflammatory Bowel Disease (IBD) is a term for chronic inflammatory conditions affecting the digestive tract, primarily Crohn ...